|
Klaus May is a Senior Advisor focused on the Asian business working out of Tokyo. Dr. May has been active in the life sciences for more than 17 years specializing in management consulting, investment banking and as entrepreneur. Dr. May is experienced in cross border M&A transactions, private equity projects, growth strategy and turn-around of companies.
Experience
Prior to joining JSB-Partners, Dr. May has founded a Specialty Pharma business focusing on South and South East Asia where he still is a board member. Before that, Dr. May has been Global Head of Healthcare and Chemicals Advisory with ABN Amro, working out of their Amsterdam and Tokyo offices where among others he focused on cross border transactions between Asian and European companies. Before joining ABN Amro, Dr. May was a senior member of The Boston Consulting Group’s Healthcare practice in their Paris and Dusseldorf offices.
Boards
Dr. May is a member of the board of directors of Sea Lion Pharma, Singapore. He previously served on the board of Ubbink bv, Netherlands.
Education
Dr. May earned a PhD degree from Max Planck Institute for Biochemistry in Martinsried, Germany and an MBA from INSEAD, Fontainebleau, France. | 